Content area
Abstract
The Theralase(TM) "biofeedback" technology is a quantum leap forward in the field of laser biostimulation, possessing the ability to precisely target injured tissue with known doses of energy. With this feedback and planning, therapeutic laser technology now has the ability to enter mainstream medicine. Laser systems currently available on the market may have error rates of greater than 3000% in the deposition of predetermined laser energy at tissue depth. The new Theralase(TM) patented technology allows the deposition of laser energy to tissue depth within an accuracy of a millimeter, over all body types, at an error rate of less than 30%."
Clinically effective dosages specific to optical tissue profiles will be stored in a HIPAA compliant central databank and be available to all practitioners utilizing the TLC-2000 therapeutic laser system, in a real time format. This central databank will contain the clinical knowledge derived from the completion of thousands of international clinical trials using laser therapy. The new TLC-2000 laser system is a "learning" device that will make the most of this database by remembering the most clinically effective treatments performed by practitioners and transmitting this information to the central databank for the benefit of all users.
Theralase(TM), in keeping with its mandate of world class customer service, will allow every Theralase(TM) customer on record the ability to trade up to the new state of the art TLC-2000 biofeedback therapeutic laser system. In order to allow all laser practitioners employing laser therapy in their practice a common tool to use in the delivery of precision therapeutic laser treatments, Theralase(TM) will also allow purchasers of competitive products the ability to trade up to the TLC-2000 biofeedback therapeutic laser system, under certain terms and conditions."